All In Biotech

Drug Trial Radar · NCT06694935

A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

A Phase 1b Study of QX1206 in Type 2 Diabetes Mellitus (T2DM) Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

Last checked: Nov 20, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Jan 6, 2025

Primary completion

Jul 2025

Study completion Dec 2025

Sponsor

Lead sponsor
1Globe Health InstituteIndustry
Sponsor type
Industry
First posted
Nov 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)
  • Non-Alcoholic Fatty Liver Disease (NAFLD)

Interventions

  • QX1206Drug

    QX1206 will be administered orally before bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D)Time frame: Baseline Day 1 up to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centricity Research Toronto LMC.

    Toronto, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.